 C4 Therapeutics Inc NASDAQ: CCC shares are trading significantly lower Friday afternoon after the company presented data from Cohort A of its ongoing Phase 12 clinical trial of CFT7455. Cohort A, the first cohort in the clinical trial, explored CFT7455 as a single agent and enrolled five. 